Research & Development
Investigational Therapeutic
for Episodic Cardiovascular Conditions
Etripamil Clinical Pipeline
| AREA OF FOCUS | PRECLINICAL | PHASE I | PHASE II | PHASE III | PHASE |
|---|---|---|---|---|---|
|
Temporary control of rapid ventricular rate |
PHASE I/II | ||||
|
Rapid conversion to sinus rhythm |
PHASE III |
Our lead pipeline candidate, etripamil, is a proprietary chemical entity that was conceived, discovered, and optimized by Milestone.
Milestone is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug, etripamil, for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT). Milestone has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Etripamil is not currently approved for the treatment of PSVT, AFib with RVR, or for any other indication anywhere in the world.
.png){kind=small}